Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission

Shohei Mizuno, Masamitsu Yanada, Koji Kawamura, Masayoshi Masuko, Naoyuki Uchida, Yukiyasu Ozawa, Koji Iwato, Kazuteru Ohashi, Kazuhiro Ikegame, Sung Won Kim, Masatsugu Tanaka, Tetsuya Eto, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Shingo Yano, Akiyoshi Takami

Research output: Contribution to journalArticlepeer-review

Abstract

Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML) confers a dismal prognosis when treated with chemotherapy alone. Data on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes are limited. We retrospectively analyzed 4649 AML patients who received allo-HCT and were in complete remission. Outcomes of Ph+ AML (n = 30), intermediate-risk, and poor-risk AML patients were compared. The 3-year overall survival after allo-HCT was similar in intermediate-risk (62.7%; 95% CI: 61.0–64.3%) and Ph+ AML (73.3%; 95% CI: 51.5–86.4%) groups (P = 0.42); however, it differed significantly between the poor-risk (49.7%; 95% CI: 45.9–53.4%) and Ph+ AML (73.3%; 95% CI: 51.5–86.4%) groups (P = 0.049). Disease-free survival in Ph+ AML patients was comparable to that in intermediate-risk patients but better than that in poor-risk patients. Relapse rates were significantly lower in Ph+ AML patients than in other groups. Non-relapse mortality (NRM) rates were similar among groups. Multivariate analysis showed that Ph+ AML was not a significant predictor of poor prognosis in terms of overall survival, disease-free survival, relapse, and NRM. Our data showed better post-transplant outcomes for Ph+ AML patients than for those with poor-risk AML. Hence, allo-HCT could be a feasible treatment option for Ph+ AML patients.

Original languageEnglish
Pages (from-to)232-242
Number of pages11
JournalBone Marrow Transplantation
Volume56
Issue number1
DOIs
StatePublished - Jan 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission'. Together they form a unique fingerprint.

Cite this